Reblozyl sales surged 35% in Q1 for BMY, but a failed phase III study clouds expansion plans amid stiff anemia drug ...

Despite not meeting the endpoint, subjects have experienced a meaningful improvement in RBC transfusion independence.

US pharma major Bristol Myers Squibb’s shares remained steady, despite the company reporting disappointing results from its ...

Bristol Myers' Reblozyl missed its primary goal in a Phase 3 anemia trial but showed positive secondary outcomes in ...

Despite a phase 3 flop, Bristol Myers Squibb—encouraged by “clinically meaningful results” and bruised by three other recent ...

Bristol Myers Squibb said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to meet the main ...

Despite the failure, BMS remains “encouraged” by Reblozyl’s clinical activity in myelofibrosis-associated anemia and will approach regulators to discuss potential submissions for this indication, for ...

Bristol Myers on Friday said the Phase 3 study of Reblozyl with concomitant janus-kinase-inhibitor therapy didn't meet its primary endpoint of red-blood-cell transfusion independence in adults with ...

The anemia treatment missed its main goal in a myelofibrosis study. Meanwhile, Blenrep's return to the U.S. market may have ...

Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 INDEPENDENCE trial evaluating Reblozyl® (luspatercept-aamt) with concomitant janus kinase inhibitor (JAKi) therapy in adult patients with ...

Study Highlights: Reblozyl, which was approved last summer, led to more patients with myelodysplastic syndromes achieving 12- and 24-week intervals of red blood cell transfusion independence compared ...

Reblozyl for anemia in patients with an MDS subset demonstrated positive effects, compared with previous treatments, according to an MDS expert.